Comparison of reported and expected deaths in sildenafil (Viagra) users.
Wysowski
Diane K
DK
Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA. wysowski@cder.fda.gov
Farinas
Evelyn
E
Swartz
Lynette
L
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D009026:Mortality; D009203:Myocardial Infarction / Q000401:mortality; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014481:United States / Q000453:epidemiology
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases